Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports

Scheen, André; Marre, Michel; Thivolet, Charles

doi:10.1016/j.diabet.2020.05.008

Cited by 129 publications

(124 citation statements)

References 67 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…21 To date, the available data do not support such a claim, but show that DPP-4 inhibitors are safe when used in patients either at risk of, or infected with COVID-19. 22,23 Such information is consistent with the results of the current study and provides further information regarding the therapeutic options for people with diabetes and COVID-19. 32 In summary, our results do not lend support to the concerns that DPP-4 inhibitors might increase the risk of pneumonia, but nor do they provide conclusive evidence of a protective effect.…”

Section: Discussionsupporting

confidence: 89%

“…18,19 More recently, given the key role played by DPP-4 in the infection by some coronaviruses responsible for acute respiratory distress syndrome, 20 it has been suggested that DPP-4 inhibitors might protect from susceptibility to or progression of COVID-19. 21 Although initial observational studies have not confirmed such a hypothesis, 22,23 there is renewed interest in the extra-glycaemic action of DPP-4 inhibitors.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Exposure to dipeptidyl‐peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta‐analysis

Morieri

Bonora

Longato

et al. 2020

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Aim Concerns have been raised that dipeptidyl‐peptidase 4 inhibitors (DPP‐4i) may increase the risk of pneumonia. We analysed observational data and clinical trials to explore whether use of DPP‐4i modifies the risk of pneumonia. Methods We identified patients with diabetes in the Veneto region administrative database and performed propensity score matching between new users of DPP‐4 inhibitors and new users of other oral glucose‐lowering medications (OGLMs). We compared the rate of hospitalization for pneumonia between matched cohorts using the Cox proportional hazard model. The same analysis was repeated using the database of a local diabetes outpatient clinic. We retrieved similar observational studies from the literature to perform a meta‐analysis. Results from trials reporting pneumonia rates among patients randomized to DPP‐4 inhibitors versus placebo/active comparators were also meta‐analysed. Results In the regional database, after matching 6495 patients/group, new users of DPP‐4 inhibitors had a lower rate of hospitalization for pneumonia than new users of other OGLMs (HR 0.76; 95% CI 0.61‐0.95). In the outpatient database, after matching 867 patients/group, new users of DPP‐4 inhibitors showed a non‐significantly lower rate of hospitalization for pneumonia (HR 0.65; 95% CI 0.41‐1.04). The meta‐analysis of observational studies yielded an overall non‐significant lower risk of hospitalization for pneumonia among DPP‐4 inhibitor users (RR 0.81; 95% CI 0.65‐1.01). The meta‐analysis of randomized controlled trials showed no overall effect of DPP‐4 inhibitors on pneumonia risk (RR 1.06; 95% CI 0.93‐1.20). Conclusion The use of DPP‐4 inhibitors can be considered as safe with regard to the risk of pneumonia.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Exposure to dipeptidyl‐peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta‐analysis

Morieri

Bonora

Longato

et al. 2020

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Last, but not least, our findings may be relevant for assessing high-risk populations susceptible to adverse consequences of COVID-19, including obese ( 145 , 146 ), hypertensive ( 4 , 10 , 12 ), and diabetic patients ( 13 ). Shared inflammatory machinery, activated by acute infectious entities and exacerbated by chronic comorbidities with active inflammation, may underlie these associations.…”

Section: Discussionmentioning

confidence: 92%

The Neat Dance of COVID-19: NEAT1, DANCR, and Co-Modulated Cholinergic RNAs Link to Inflammation

2020

View full text Add to dashboard Cite

The COVID-19 pandemic exerts inflammation-related parasympathetic complications and post-infection manifestations with major inter-individual variability. To seek the corresponding transcriptomic origins for the impact of COVID-19 infection and its aftermath consequences, we sought the relevance of long and short non-coding RNAs (ncRNAs) for susceptibility to COVID-19 infection. We selected inflammation-prone men and women of diverse ages among the cohort of Genome Tissue expression (GTEx) by mining RNA-seq datasets from their lung, and blood tissues, followed by quantitative qRT-PCR, bioinformatics-based network analyses and thorough statistics compared to brain cell culture and infection tests with COVID-19 and H1N1 viruses. In lung tissues from 57 inflammation-prone, but not other GTEx donors, we discovered sharp declines of the lung pathology-associated ncRNA DANCR and the nuclear paraspeckles forming neuroprotective ncRNA NEAT1. Accompanying increases in the acetylcholine-regulating transcripts capable of controlling inflammation co-appeared in SARS-CoV-2 infected but not H1N1 influenza infected lung cells. The lung cells-characteristic DANCR and NEAT1 association with inflammation-controlling transcripts could not be observed in blood cells, weakened with age and presented sex-dependent links in GTEx lung RNA-seq dataset. Supporting active involvement in the inflammatory risks accompanying COVID-19, DANCR’s decline associated with decrease of the COVID-19-related cellular transcript ACE2 and with sex-related increases in coding transcripts potentiating acetylcholine signaling. Furthermore, transcription factors (TFs) in lung, brain and cultured infected cells created networks with the candidate transcripts, indicating tissue-specific expression patterns. Supporting links of post-infection inflammatory and cognitive damages with cholinergic mal-functioning, man and woman-originated cultured cholinergic neurons presented differentiation-related increases of DANCR and NEAT1 targeting microRNAs. Briefly, changes in ncRNAs and TFs from inflammation-prone human lung tissues, SARS-CoV-2-infected lung cells and man and woman-derived differentiated cholinergic neurons reflected the inflammatory pathobiology related to COVID-19. By shifting ncRNA differences into comparative diagnostic and therapeutic profiles, our RNA-sequencing based Resource can identify ncRNA regulating candidates for COVID-19 and its associated immediate and predicted long-term inflammation and neurological complications, and sex-related therapeutics thereof. Our findings encourage diagnostics of involved tissue, and further investigation of NEAT1-inducing statins and anti-cholinergic medications in the COVID-19 context.

show abstract

“…Emerging data consistently show that diabetes mellitus is associated with increased morbidity and mortality in COVID-19 patients [1] , [2] , recently confirmed in a very large epidemiological study of the UK General Practice population [3] . On the other hand, there have been reports of deterioration of glycemic control, including episodes of ketosis, ketoacidosis, or hyperosmolar hyperglycaemic state in type 2 diabetes patients with COVID-19, requiring exceptionally high doses of insulin [1] , [4] . Further, recent reports show an increase in new-onset type 1 diabetes, possibly linked to COVID-19, firstly in a US-based population [5] and subsequently, in a cohort of children living in North West London [6] .…”

mentioning

confidence: 99%

Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes

Sathish

Tapp

Cooper

et al. 2021

Diabetes & Metabolism

101

View full text Add to dashboard Cite

Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports

Cited by 129 publications

References 67 publications

Exposure to dipeptidyl‐peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta‐analysis

Exposure to dipeptidyl‐peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta‐analysis

The Neat Dance of COVID-19: NEAT1, DANCR, and Co-Modulated Cholinergic RNAs Link to Inflammation

Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes

Contact Info

Product

Resources

About